NASDAQ:JNP Juniper Pharmaceuticals (JNP) Stock Price, News & Analysis → $5,000 Gold? (From Stansberry Research) (Ad) Free JNP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$11.45▼$11.5050-Day Range N/A52-Week Range$4.30▼$13.25Volume28,513 shsAverage Volume155,873 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Juniper Pharmaceuticals alerts: Email Address Ad Stansberry ResearchUrgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.Find out for free here. About Juniper Pharmaceuticals Stock (NASDAQ:JNP)Juniper Pharmaceuticals, Inc., a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women's health. It operates in two segments, Product and Service. The company develops its products utilizing its proprietary drug delivery technologies, which include bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa to achieve sustained and controlled delivery of active drug product; and a novel intravaginal ring technology. Juniper Pharmaceuticals, Inc. markets Crinone, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency. Its product candidates include JNP-0101, which is designed to deliver oxybutynin for the treatment of overactive bladder in women; JNP-0201, which contains natural progesterone and estradiol to be used for hormone replacement therapy in menopausal women; and JNP-0301, a natural progesterone for the prevention of preterm birth in women with a short cervical length. The company offers pharmaceutical product development; clinical trial manufacturing; and analytical and consulting services. Juniper Pharmaceuticals, Inc. has collaboration agreements with Merck KGaA and Allergan, as well as patent license agreement with Massachusetts General Hospital. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.Read More Ad Stansberry ResearchUrgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.Find out for free here. JNP Stock News HeadlinesJanuary 30, 2024 | msn.comJuniper Networks revenue misses estimates on weak client spendingJanuary 9, 2024 | msn.comWhy Juniper Networks Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving PremarketMay 2, 2024 | Paradigm Press (Ad)Biden out June 13; Kamala won’t replace him?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.November 24, 2023 | benzinga.comJuniper Networks Stock (NYSE:JNPR), Analyst Ratings, Price Targets, PredictionsOctober 20, 2022 | marketwatch.comJuniper Essential Oil Market : Reliable Business Data Analysis and Forecast by 2028 with Top Countries DataOctober 27, 2021 | finance.yahoo.comZafgen (ZFGN) Presents Favorable New Data on BeloranibSee More Headlines Receive JNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Juniper Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2018Today5/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:JNP CUSIPN/A CIK821995 Webwww.juniperpharma.com Phone617-639-1500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Alicia Secor (Age 55)Pres, CEO & Director Mr. Jeffrey E. Young (Age 45)CFO, Sr. VP of Fin., Treasurer & Sec. Dr. Nikin Patel (Age 45)COO & Director Dr. Shen Luk BScPh.D., Chief Scientific OfficerDr. Claire Madden-Smith BScPh.D., Sr. VP of Juniper Pharma ServicesKey CompetitorsContext TherapeuticsNASDAQ:CNTXLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPPharvarisNASDAQ:PHVSView All Competitors JNP Stock Analysis - Frequently Asked Questions How were Juniper Pharmaceuticals' earnings last quarter? Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) issued its earnings results on Thursday, August, 9th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of $0.04 by $0.18. The specialty pharmaceutical company earned $15.31 million during the quarter, compared to analyst estimates of $16.30 million. What other stocks do shareholders of Juniper Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Juniper Pharmaceuticals investors own include Novavax (NVAX), Idera Pharmaceuticals (IDRA), Madrigal Pharmaceuticals (MDGL), Synergy Pharmaceuticals (SGYP), Verastem (VSTM), CRISPR Therapeutics (CRSP), Evoke Pharma (EVOK), Exelixis (EXEL), Amicus Therapeutics (FOLD) and Galectin Therapeutics (GALT). This page (NASDAQ:JNP) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTruth about Trump you’ve never heardPorter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithAI “wealth window” is closing June 25thParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Juniper Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.